Radioimmunotherapy with 90Y-Zevalin in mantle cell lymphoma patients.

被引：0
|
作者：
Sowa-Staszczak, A.
Hubalewska-Dydejczyk, A.
Jurczak, W.
Huszno, B.
Giza, A.
Wegrzyn, J.
Skotnicki, A.
机构：
[1] Jagiellonian Univ, Dept Endocrinol, Coll Med, Nucl Med Unit, Krakow, Poland
[2] Jagiellonian Univ, Dept Hematol, Coll Med, Krakow, Poland
[3] Jagiellonian Univ, Chair Hematol, Coll Med, Krakow, Poland
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2006年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S195 / S195
页数：1
相关论文
共 50 条
  • [31] A comparison of techniques for analysing 90Y-Zevalin thin-layer chromatography plates
    O'Brien, LM
    Waight, CC
    Millar, AM
    NUCLEAR MEDICINE COMMUNICATIONS, 2005, 26 (02) : 163 - 166
  • [32] Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma
    Witzig, TE
    SEMINARS IN ONCOLOGY, 2003, 30 (06) : 11 - 16
  • [33] DEVELOPMENT OF ANTHROPOMORPHIC HAND PHANTOMS FOR PERSONAL DOSIMETRY IN 90Y-ZEVALIN PREPARATION AND PATIENT DELIVERING
    Ciolini, R.
    d'Errico, F.
    Traino, A. C.
    Paternostro, E.
    Lagana, A.
    Romei, C.
    Pazzagli, F.
    Del Gratta, A.
    RADIATION PROTECTION DOSIMETRY, 2014, 158 (02) : 216 - 220
  • [34] QUALITY OF LIFE, OUTCOMES, AND COSTS IN THE BELGIAN POPULATION RECEIVING 90Y-ZEVALIN FOR NON-HODGKIN LYMPHOMA: A STUDY FOR REIMBURSEMENT REVISION
    Caekelbergh, K.
    Moeremans, K.
    VALUE IN HEALTH, 2010, 13 (07) : A276 - A276
  • [35] Urinary clearance of 90Y activity following Zevalin™ radioimmunotherapy of B-cell non-Hodgkin's lymphoma.
    Wiseman, GA
    Leigh, BR
    Erwin, WD
    Raubitschek, A
    Silverman, DH
    Lamonica, D
    Gansen, D
    Grillo-Lopez, AJ
    White, CA
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 268P - 268P
  • [36] Evaluation of different beta-counting systems involved in 90Y-Zevalin quality control
    Urbano, Nicoletta
    Modoni, Sergio
    NUCLEAR MEDICINE COMMUNICATIONS, 2007, 28 (12) : 943 - 950
  • [37] A phase I/II trial of radioimmunotherapy (RIT) with 90Yttrium-Ibritumomab tiuxetan (Zevalin®; 90Y-Zevalin) combined with the redox-active agent motexafin gadolinium (MGd):: Prompt and high remission rates in patients with rituximab-refractory non-Hodgkin's lymphoma (NHL)
    Evens, Andrew M.
    Spies, Stewart
    Patton, David
    Helenowski, Irene
    Jovanovic, Borko
    Miyata, Sarah
    Hamilton, Elizabeth
    Saville, M. Wayne
    Miller, Richard A.
    Winter, Jane N.
    Gordon, Leo I.
    BLOOD, 2007, 110 (11) : 754A - 754A
  • [38] Improvements in health-related quality of life of patients with DLBCL after treatment with yttrium-90 ibritumomab tiuxetan (90y-Zevalin)
    Thompson, SS
    Macran, S
    Kalmus, J
    Morschhauser, F
    Hugh-Jones, C
    BLOOD, 2005, 106 (11) : 279B - 279B
  • [39] A phase II study of 90Yttrium-ibritumomab (Zevalin) for the treatment of patients with relapsed and refractory mantle cell lymphoma (MCL).
    Younes, A
    Pro, B
    Delpassand, E
    McLaughlin, P
    Romaguera, J
    Wang, M
    BLOOD, 2003, 102 (11) : 406A - 406A
  • [40] A phase 2 study of 90Y-Ibritumomab tiuxetan (90Y-Zevalin®) in relapsed/refractory non-Hodgkin's lymphoma:: Preliminary report of the Argentinean cooperative group.
    Cacchione, Roberto E.
    Milone, Jorge
    Bordone, Javier
    Dupont, Juan
    Milone, Gustavo
    Riveros, Dardo
    Negri, Pedro
    Ardaiz, Maria
    Riera, Leandro
    Foncuberta, Maria Cecilia
    Bezares, Fernando
    BLOOD, 2006, 108 (11) : 254B - 254B
12345